News

The agreements are expected to expand the application of Codexis’ technology to a broadened pipeline of branded innovator pharmaceutical products. As per the new agreements, Codexis will apply

GDC-0449 was discovered by Genentech, under the ongoing collaboration agreement between Genentech and Curis, and was jointly validated through a series of preclinical studies. Through this partnership, the

To support a whole product solution with the commercial launch of the SMRT system in the second half of 2010, Pacific Biosciences has developed a formal partner program

The acquisition expands AMRI’s portfolio of development and large scale manufacturing facilities as well as its customer portfolio, with little overlap of customers between the two companies. The

Roche’s investigational AmpliChip p53 Test is designed to detect damage to p53 DNA in tumor cells in order to identify which cells carry dysfunctional p53 proteins that can

Conny Bogentoft, CEO of Karolinska Development, said: “Aprea is developing a new class of anticancer drugs for the treatment of acute myelogenous leukemia, the most common acute leukemia

The alliance aims to discover and develop antibody therapeutics based on novel modes of action in bone and joint diseases, including rheumatoid arthritis, osteoporosis and osteoarthritis. As part

The two products are intended for the relief of different symptoms and contain different active ingredients. Maalox Total Relief is an upset stomach reliever and anti-diarrheal medication, while

Roche’s investigational AmpliChip p53 Test is designed to detect damage to p53 DNA in tumor cells in order to identify which cells carry dysfunctional p53 proteins that can